Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) confirmed on Thursday that it has completed the acquisition of Yellow Jersey Therapeutics for USD1.25bn.

Through this transaction J&J secures the global rights to NM26, a Phase 2-ready bispecific antibody targeting two pathways in atopic dermatitis.

NM26 targets IL-4R alpha subunit and IL-31, which trigger skin inflammation and itch. Atopic dermatitis is a common inflammatory skin disease causing itching, inflammation and increased risk of infections.

J&J aims to expand its treatment options for atopic dermatitis and other immune-mediated diseases.